Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases

• US 20050208102A1
• Filed: 04/09/2004
• Published: 09/22/2005
• Est. Priority Date: 04/09/2003
• Status: Abandoned Application

• Current Assignee: Rapidheal LLC
• Original Assignee: Rapidheal LLC
• Inventors: Schultz, Clyde L.
• Application Number:
  US10/821,718
• Publication Number:
  US 20050208102A1
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61K 31/075 Ethers or acetals
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/65 Tetracyclines
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00

Abstract

This invention provides a polymeric drug delivery system including a hydrogel containing one or more drugs for the treatment of a posterior segment disease. Allowing passive transference of this drug from a dilute solution into the hydrogel produces the delivery system. The hydrogel, when placed in contact with the eye, delivers the drug. The delivery of the drug is sustained over an extended period of time, which is of particular utility in the eye, which is periodically flushed with tears. This sustained delivery accelerates the treatment process while avoiding potential damaging effects of localized delivery of high concentrations of compounds, e.g., from eye drops.

Claims

3-1. The hydrogel of claim 1, wherein said drug is an anti-infective;

analgesic;

anesthetic;

antiallergenic agent;

mast cell stabilizer;

steroidal or non-steroidal anti-inflammatory agent;

decongestant;

antioxidant;

nutritional supplement;

angiogenesis inhibitor;

antimetabolite;

fibrinolytic;

neuroprotective drug;

angiostatic steroid;

mydriatic;

cyclopegic mydriatic;

miotic;

vasoconstrictor;

vasodilator;

anticlotting agent;

anticancer agent;

antisense agent, immunomodulatory agent;

carbonic anhydrase inhibitor;

integrin antagonist;

cyclooxgenase inhibitor;

differentiation modulator agent;

sympathomimetic agent;

VEGF antagonist;

immunosuppresant agent;

or combination or prodrug thereof.

19. A method of fabricating a polymeric hydrogel, said method comprising the steps of contacting said polymeric hydrogel with a solution of a drug capable of treating a posterior segment disease, wherein said drug is passively transferred into said hydrogel.